Regine Pappas, MD
Ophthalmology · Melbourne, FLNPI 1215921275
Payments from drug & device makers
Across 458 payments — averaging $105.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$16K
- AbbVie$11K
- Alcon$7K
- Nova Eye, Inc.$6K
- Eyepoint US, Inc.$1K
- Glaukos Corporation$1K
- plus $6K from 25 others
What the payments were for
- Consulting fees$13,93829%
- Speaking & faculty fees$15,45732%
- Travel & lodging$2,5085%
- Food & beverage$16,34034%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 37 | $16,122 |
| AbbVie(2 entities) | 204 | $11,081 |
| Alcon | 33 | $6,868 |
| Nova Eye, Inc. | 2 | $6,218 |
| Eyepoint US, Inc. | 2 | $1,317 |
| Glaukos Corporation | 3 | $1,033 |
| NEW World Medical,inc. | 33 | $807 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $610 |
| Bausch & Lomb Americas Inc. | 15 | $558 |
| Sight Sciences, Inc. | 14 | $532 |
| Lensar, Inc. | 2 | $512 |
| Sun Pharmaceutical Industries Inc. | 12 | $394 |
| Mallinckrodt Hospital Products Inc. | 15 | $383 |
| Novartis | 15 | $318 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $272 |
| Oyster Point Pharma, Inc. | 5 | $248 |
| Harrow Eye, LLC | 7 | $183 |
| Amgen | 3 | $179 |
| Dompe US, Inc. | 2 | $155 |
| Carl Zeiss Meditec USA, Inc. | 1 | $97 |
| Rayner Intraocular Lenses Limited | 3 | $73 |
| Biotissue Holdings Inc. | 3 | $48 |
| Carl Zeiss Meditec, Inc. | 2 | $42 |
| Iridex Corporation | 2 | $39 |
| Eyevance Pharmaceuticals LLC | 2 | $38 |
| Halozyme Inc | 2 | $37 |
| Omeros Corporation | 2 | $37 |
| Thea Pharma Inc. | 1 | $28 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Akorn, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$21,584
- Rhopressa$16,210
- DURYSTA$1,996
- XEN$1,913
- DEXYCU$1,317
- XEN GLAUCOMA TREATMENT SYSTEM$1,115
- LUMIGAN$826
- LENSAR LASER SYSTEM$512
- VYZULTA$207
- MIEBO$207
- Ahmed Glaucoma Valve$199
- Kahook Dual Blade$199
- OMNI(R) SURGICAL SYSTEM (US)$149
- iDoseTR$130
- RESTASIS MULTIDOSE$130
- OZURDEX$130
- Oxervate$121
- Tecnis Simplicity$111
- TYRVAYA$108
- Ryzumvi$108
How this compares
$48,288 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 395 | $203,714 |
| RestasisCyclosporine | 108 | $128,518 |
| XiidraLifitegrast | 27 | $50,410 |
| RocklatanNetarsudil Mesylat/Latanoprost | 90 | $47,084 |
| CombiganBrimonidine Tartrate/Timolol | 120 | $41,896 |
| VevyeCyclosporine | 42 | $37,710 |
| Travoprost | 199 | $34,137 |
| VyzultaLatanoprostene Bunod | 65 | $33,685 |
| IlevroNepafenac | 92 | $33,682 |
| MieboPerfluorohexyloctane/Pf | 34 | $29,621 |
| RhopressaNetarsudil Mesylate | 61 | $27,786 |
| Brinzolamide | 106 | $23,807 |
| Cyclosporine | 33 | $21,104 |
| Alphagan PBrimonidine Tartrate | 56 | $19,470 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 83 | $18,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $11,081 | $393,598679 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $558 | $113,717126 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $16,122 | $74,870151 claims |
| Harrow Eye, LLCVevye | $183 | $37,71042 claims |
| NovartisIlevro | $318 | $33,68292 claims |
| AlconSimbrinza | $6,868 | $18,55683 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $610 | $18,42370 claims |
| Akorn, Inc.Betimol | $14 | $1,74311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Melbourne
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.